Clinical Trial Update: Pharmacogenomic Study for Providing Personalized Strategy to the Treatment of Non-small Cell Lung Cancer (NSCLC) IIIB/IV [Phase 2]

View source ↗

Summary

A Phase 2 pharmacogenomic study aimed at personalizing treatment strategies for advanced non-small cell lung cancer (NSCLC) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED